Navigation MenuRealWire Limited

Delivering Relevance, Releasing Influence

Tweet Facebook LinkedIn
Press Release

PAREXEL International appoints Simon Harford as Senior Vice President and Chief Financial Officer


Appointment Effective June 1, 2017

LONDON, February 28, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of Simon Harford as Senior Vice President and Chief Financial Officer effective June 1, 2017. He will serve on PAREXEL's Business Review Committee, the Company's senior-most leadership team, and assist in developing and implementing PAREXEL's strategic objectives. Mr. Harford will be based at the Company’s corporate headquarters in Waltham, Massachusetts.

“Simon brings to PAREXEL more than three decades of global financial management and investor relations experience in the pharmaceutical industry. During his career, he has successfully managed large global finance functions, implemented transformational projects, and improved operational effectiveness,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL. “Simon’s leadership will strengthen our ability to accelerate growth and improve profitability as we implement our corporate strategy.”

Mr. Harford joins PAREXEL from GlaxoSmithKline plc (GSK), where he most recently served as Senior Vice President, Finance, for the company’s Global Pharmaceuticals business based at GSK’s global headquarters in Brentford, England. Prior to joining GSK, Mr. Harford served as Group Vice President and Controller for Avon Products, Inc., in New York. Additionally, he spent two decades with Eli Lilly and Company in various finance leadership roles across Europe and in Indianapolis, most notably as Head of Investor Relations and as Vice President and Controller.

“PAREXEL has a long and distinguished history of providing innovative services to the biopharmaceutical industry, a record that has positioned the Company for long-term growth,” said Mr. Harford. “I look forward to working with PAREXEL’s management team as we leverage growth opportunities and deliver value to our shareholders.”

Mr. Harford, a native of the United Kingdom, holds an MBA from the University of Virginia’s Darden Graduate School of Business. 

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the second quarter. For more information about PAREXEL International visit

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

# # #

Erik Kopp
Tel.: +1 781-434-5304

Jenny Radloff, PAN Communications
Tel: +1 617-502-4300

Ronald Aldridge
Tel.: +1-781-434-4753